Alexander brings over a decade of experience in mRNA and LNP technologies, gained across both academia and the pharmaceutical industry. After earning his Diploma degree, he specialized in nucleic acid chemistry and nanostructuring, completing his PhD at the University of Stuttgart.
Throughout his career, he has worked extensively with complex nucleic acid modalities and built a strong scientific track record with numerous publications. At CureVac SE in Germany, he held roles of increasing responsibility, contributing to the advancement of RNA-based therapeutics.
Since June 2023, Alexander has been leading process development for nucleic acid delivery systems at Lonza in the Netherlands, and since 2024 he has also been coordinating the entire AD&PD area.
In these roles, he is committed to driving innovation and advancing nucleic acid delivery to the next level.
